Status:
COMPLETED
Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes
Lead Sponsor:
Solvay Pharmaceuticals
Conditions:
Type 2 Diabetes
Hypogonadism
Eligibility:
MALE
30-80 years
Phase:
PHASE2
Brief Summary
This study is to investigate how well Androgel, when tested against placebo gel, helps to control blood sugar levels in males with type 2 diabetes who have low testosterone (the main male hormone) blo...
Eligibility Criteria
Inclusion
- Able to read and write
- Males
- Between 30-80 years old
- Have type 2 diabetes
- Diagnoses of hypogonadism or low testosterone
Exclusion
- On insulin monotherapy
- Use of testosterone therapy within the last 6 months
- Male breast cancer
- History of prostate cancer
- History of clinically significant sleep apnea
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
June 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00141492
Start Date
October 1 2004
End Date
June 1 2007
Last Update
January 21 2015
Active Locations (70)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 58
Birmingham, Alabama, United States
2
Site 67
Calera, Alabama, United States
3
Site 54
Mobile, Alabama, United States
4
Site 16
Phoenix, Arizona, United States